nitrendipine has been researched along with eprosartan in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (87.50) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Berger, J; Diener, HC; Dominiak, P; Hammersen, F; Kulschewski, A; Lüders, S; Plate, K; Schrader, J; Zidek, W | 1 |
| Basile, J; Bloch, MJ | 1 |
| Boulanger, JM; Hill, MD | 1 |
| Strauss, MH; Verma, S | 1 |
| Boysen, G; Hornnes, N; Larsen, K | 1 |
| Johnston, SC | 1 |
| de la Sierra, A | 1 |
| Dowlatshahi, D; Hill, MD | 1 |
| Diener, HC; Gradl, B; Greiner, W; Jönsson, B; Lindgren, P; Lüders, S; Schrader, J; Schwander, B; Villar, FA; Zöllner, Y | 1 |
| Plosker, GL | 1 |
2 review(s) available for nitrendipine and eprosartan
| Article | Year |
|---|---|
Effects of eprosartan on target organ protection.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Endothelium, Vascular; Humans; Hypertension; Imidazoles; Neuroprotective Agents; Nitrendipine; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Risk Factors; Stroke; Thiophenes; Treatment Outcome | 2006 |
Eprosartan: a review of its use in hypertension.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Clinical Trials as Topic; Cough; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Incidence; Nitrendipine; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Recurrence; Risk Factors; Sodium Chloride Symporter Inhibitors; Thiophenes; Treatment Outcome | 2009 |
3 trial(s) available for nitrendipine and eprosartan
| Article | Year |
|---|---|
Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Topics: Acrylates; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Mass Index; Calcium; Cardiovascular Diseases; Female; Humans; Hypertension; Imidazoles; Magnetic Resonance Spectroscopy; Male; Middle Aged; Nitrendipine; Prospective Studies; Recurrence; Risk Factors; Single-Blind Method; Sodium Chloride Symporter Inhibitors; Stroke; Thiophenes; Time Factors; Treatment Outcome | 2005 |
Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
Topics: Acrylates; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Data Interpretation, Statistical; Diuretics; Humans; Imidazoles; Internal Medicine; Ischemic Attack, Transient; Morbidity; Neurology; Nitrendipine; Prospective Studies; Stroke; Thiophenes | 2006 |
MOSES raises questions.
Topics: Acrylates; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Data Interpretation, Statistical; Humans; Imidazoles; Ischemic Attack, Transient; Nitrendipine; Research Design; Risk Factors; Stroke; Thiophenes | 2006 |
11 other study(ies) available for nitrendipine and eprosartan
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Humans; Hypertension; Imidazoles; Nitrendipine; Randomized Controlled Trials as Topic; Stroke; Survival Rate; Thiophenes | 2005 |
Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Humans; Imidazoles; Nitrendipine; Randomized Controlled Trials as Topic; Stroke; Thiophenes | 2006 |
Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Follow-Up Studies; Humans; Imidazoles; Multicenter Studies as Topic; Nitrendipine; Prospective Studies; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Treatment Outcome | 2006 |
[Not all antihypertensive agents protect equally well].
Topics: Acrylates; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Diuretics; Follow-Up Studies; Humans; Hypertension; Imidazoles; Meta-Analysis as Topic; Nitrendipine; Primary Prevention; Risk Factors; Stroke; Thiophenes; Time Factors | 2006 |
Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Topics: Acrylates; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Humans; Hypertension; Imidazoles; Ischemic Attack, Transient; Male; Nitrendipine; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thiophenes | 2009 |
Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
Topics: Acrylates; Antihypertensive Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Enalapril; Europe; Geography; Humans; Hypertension; Imidazoles; Male; Meta-Analysis as Topic; Middle Aged; Monte Carlo Method; Nitrendipine; Primary Prevention; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Stroke; Thiophenes | 2009 |